Disc Medicine Inc

IRON

Company Profile

  • Business description

    Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company’s preclinical programs include DISC-0998.

  • Contact

    321 Arsenal Street
    Suite 101
    WatertownMA02472
    USA

    T: +1 617 674-9274

    https://www.discmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    84

Stocks News & Analysis

stocks

Unwarranted drop in ASX share

Jittery investors misinterpret an audit for an existential crisis.
stocks

Macquarie: A return to group-wide growth

Our view on the shares after earnings.
stocks

After earnings, is Disney stock a buy, a sell, or fairly valued? -

Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,184.800.300.00%
CAC 408,327.884.600.06%
DAX 4024,987.8527.02-0.11%
Dow JONES (US)50,188.1452.270.10%
FTSE 10010,353.8432.39-0.31%
HKSE27,183.15155.990.58%
NASDAQ23,102.47136.20-0.59%
Nikkei 22557,650.541,286.602.28%
NZX 50 Index13,496.2149.840.37%
S&P 5006,941.8123.01-0.33%
S&P/ASX 2008,918.902.900.03%
SSE Composite Index4,128.375.280.13%

Market Movers